Shannon N. Westin, MD, MPH, FACOG
Articles
Recent Updates in PARP Inhibitor Indications for Ovarian Cancer
Bradley J. Monk, MD, FACS, FACOG;Robert L. Coleman, MD, FACOG, FACS;Shannon N. Westin, MD, MPH, FACOG;Michael J Birrer, MD, PhD
October 6th 2022Dr Robert Coleman reviews data from the ARIEL-4 trial on rucaparib in recurrent ovarian cancer, sparking a discussion on PARP inhibitor use.
Read More
Emerging Data From Ongoing IO Combination Trials in EC
May 19th 2021Shannon N. Westin, MD, MPH, FACOG, and Vicky Makker, MD, comment on data from ongoing clinical trials presented at the Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer for the management of advanced endometrial cancer.
Read More
Upcoming Clinical Trials for Ovarian Cancer
Bradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology;Michael J. Birrer, MD, PhD, University of Arkansas Medical Center;Matthew Powell, MD, Washington University School of Medicine;Leslie Randall, MD, FACOG, VCU Health;Shannon N. Westin, MD, MPH, FACOG
July 20th 2020Read More
Emerging Therapies in Recurrent Ovarian Cancer
Bradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology;Michael J. Birrer, MD, PhD, University of Arkansas Medical Center;Matthew Powell, MD, Washington University School of Medicine;Leslie Randall, MD, FACOG, VCU Health;Shannon N. Westin, MD, MPH, FACOG
July 20th 2020Read More
Antibody Drug Conjugates for Ovarian Cancer
Bradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology;Michael J. Birrer, MD, PhD, University of Arkansas Medical Center;Matthew Powell, MD, Washington University School of Medicine;Leslie Randall, MD, FACOG, VCU Health;Shannon N. Westin, MD, MPH, FACOG
July 20th 2020Read More
Neoadjuvant Therapy Versus Surgery for Ovarian Cancer
Bradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology;Michael J. Birrer, MD, PhD, University of Arkansas Medical Center;Matthew Powell, MD, Washington University School of Medicine;Leslie Randall, MD, FACOG, VCU Health;Shannon N. Westin, MD, MPH, FACOG
July 20th 2020Read More
New Data for Secondary Surgery in Ovarian Cancer
Bradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology;Michael J. Birrer, MD, PhD, University of Arkansas Medical Center;Matthew Powell, MD, Washington University School of Medicine;Leslie Randall, MD, FACOG, VCU Health;Shannon N. Westin, MD, MPH, FACOG
July 20th 2020Read More
PARP Inhibitors in Recurrent Ovarian Cancer
Bradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology;Michael J. Birrer, MD, PhD, University of Arkansas Medical Center;Matthew Powell, MD, Washington University School of Medicine;Leslie Randall, MD, FACOG, VCU Health;Shannon N. Westin, MD, MPH, FACOG
July 20th 2020Read More
Expert Approaches for Treating Recurrent Ovarian Cancer
Bradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology;Michael J. Birrer, MD, PhD, University of Arkansas Medical Center;Matthew Powell, MD, Washington University School of Medicine;Leslie Randall, MD, FACOG, VCU Health;Shannon N. Westin, MD, MPH, FACOG
July 20th 2020Read More
Emerging Combinations in the Frontline Setting of Ovarian Cancer
Bradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology;Michael J. Birrer, MD, PhD, University of Arkansas Medical Center;Matthew Powell, MD, Washington University School of Medicine;Leslie Randall, MD, FACOG, VCU Health;Shannon N. Westin, MD, MPH, FACOG
July 20th 2020Read More
Patient Preference for Treatment in Ovarian Cancer
Bradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology;Michael J. Birrer, MD, PhD, University of Arkansas Medical Center;Matthew Powell, MD, Washington University School of Medicine;Leslie Randall, MD, FACOG, VCU Health;Shannon N. Westin, MD, MPH, FACOG
July 20th 2020Read More
PAOLA-1 Study Surgical Subset for Ovarian Cancer
Bradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology;Michael J. Birrer, MD, PhD, University of Arkansas Medical Center;Matthew Powell, MD, Washington University School of Medicine;Leslie Randall, MD, FACOG, VCU Health;Shannon N. Westin, MD, MPH, FACOG
July 20th 2020Read More
NCCN Guidelines and FDA Approvals for Treating Ovarian Cancer
Bradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology;Michael J. Birrer, MD, PhD, University of Arkansas Medical Center;Matthew Powell, MD, Washington University School of Medicine;Leslie Randall, MD, FACOG, VCU Health;Shannon N. Westin, MD, MPH, FACOG
July 20th 2020Read More
Personalized Dosing of Niraparib in Ovarian Cancer
Bradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology;Michael J. Birrer, MD, PhD, University of Arkansas Medical Center;Matthew Powell, MD, Washington University School of Medicine;Leslie Randall, MD, FACOG, VCU Health;Shannon N. Westin, MD, MPH, FACOG
July 20th 2020Read More
Treating Homologous Recombination Proficient Ovarian Cancer
Bradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology;Michael J. Birrer, MD, PhD, University of Arkansas Medical Center;Matthew Powell, MD, Washington University School of Medicine;Leslie Randall, MD, FACOG, VCU Health;Shannon N. Westin, MD, MPH, FACOG
July 20th 2020Read More
Bradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology;Michael J. Birrer, MD, PhD, University of Arkansas Medical Center;Matthew Powell, MD, Washington University School of Medicine;Leslie Randall, MD, FACOG, VCU Health;Shannon N. Westin, MD, MPH, FACOG
July 20th 2020Read More
Need for Frontline Comparison Trials in Ovarian Cancer
Bradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology;Michael J. Birrer, MD, PhD, University of Arkansas Medical Center;Matthew Powell, MD, Washington University School of Medicine;Leslie Randall, MD, FACOG, VCU Health;Shannon N. Westin, MD, MPH, FACOG
July 20th 2020Read More
Impact of HRD Status on Frontline Treatment of Ovarian Cancer
Bradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology;Michael J. Birrer, MD, PhD, University of Arkansas Medical Center;Matthew Powell, MD, Washington University School of Medicine;Leslie Randall, MD, FACOG, VCU Health;Shannon N. Westin, MD, MPH, FACOG
July 20th 2020Read More
The Impact of PAOLA-1 on Frontline Treatment of Ovarian Cancer
Bradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology;Michael J. Birrer, MD, PhD, University of Arkansas Medical Center;Matthew Powell, MD, Washington University School of Medicine;Leslie Randall, MD, FACOG, VCU Health;Shannon N. Westin, MD, MPH, FACOG
July 20th 2020Read More
Biomarker-Driven Frontline Ovarian Cancer Treatment
Bradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology;Michael J. Birrer, MD, PhD, University of Arkansas Medical Center;Matthew Powell, MD, Washington University School of Medicine;Leslie Randall, MD, FACOG, VCU Health;Shannon N. Westin, MD, MPH, FACOG
July 20th 2020Read More
An Introduction to the Discussion of Ovarian Cancer
Bradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology;Michael J. Birrer, MD, PhD, University of Arkansas Medical Center;Matthew Powell, MD, Washington University School of Medicine;Leslie Randall, MD, FACOG, VCU Health;Shannon N. Westin, MD, MPH, FACOG
July 20th 2020Read More
Latest Updated Articles
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
